Interleukin awarded US patent for asthma test:
This article was originally published in Clinica
Executive Summary
Interleukin Genetics has received a US patent covering its pharmacogenetic tests for asthma. The patent is based on studies by the Waltham, Massachusetts firm and its collaborators that show specific variations in the interleukin-13 gene may be used to help predict an individual's response to different asthma drugs, and to identify individuals who are likely to develop more severe asthma. According to the US National Institutes of Health, around 17 million of the country's citizens have asthma.